Trial Profile
A Phase II Trial of Osimertinib (AZD9291) With or Without Bevacizumab in Patients With EGFR Mutation Positive NSCLC and Brain Metastases
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Osimertinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 04 Jul 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 04 Jul 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2024.
- 02 Jul 2022 Planned End Date changed from 1 Jul 2022 to 1 Jul 2023.